Skip to main content

Table 1 Summary of neonatal nTg mice injected with αS proteins a

From: Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein

Mouse strain Inoculum Age at harvest Number of mice Pathological findings
C57BL6/C3H fib αS (2 μl of 1 mg/ml) 1 month 9 No inclusions
C57BL6/C3H fib αS (2 μl of 1 mg/ml) 2 months 3 No inclusions
C57BL6/C3H fib αS (2 μl of 1 mg/ml) 4 months 6 No inclusions
C57BL6/C3H fib αS (2 μl of 1 mg/ml) 8 months 4 No inclusions
C57BL6/C3H fib αS (5 μl of 5 mg/ml) 1 month 9 No inclusions
C57BL6/C3H fib αS (5 μl of 5 mg/ml) 2 months 7 1 of 7 mice show rare inclusionsb
C57BL6/C3H fib αS (5 μl of 5 mg/ml) 4 months 3 No inclusions
C57BL6/C3H fib αS (5 μl of 5 mg/ml) 8 months 13 4 of 13 mice show rare cortical inclusionsc
C57BL6/C3H Δ71-82 αS (2 μl of 1 mg/ml) 1 month 4 No inclusions
C57BL6/C3H Δ71-82 αS (2 μl of 1 mg/ml) 2 months 3 No inclusions
C57BL6/C3H Δ71-82 αS (2 μl of 1 mg/ml) 4 months 2 No inclusions
C57BL6/C3H Δ71-82 αS (5 μl of 5 mg/ml) 1 month 9 No inclusions
C57BL6/C3H Δ71-82 αS (5 μl of 5 mg/ml) 2 months 8 No inclusions
C57BL6/C3H Δ71-82 αS (5 μl of 5 mg/ml) 8 months 6 No inclusions
  1. anTg mice were injected with 21–140 human αS fibrils (fib) or Δ71-82 human αS at the different dosages indicated and analyzed for αS pathology at 1–8 months post-injection using pSer129 and Syn506 antibodies.
  2. bSparse inclusions were observed in the midbrain area of 1 mouse.
  3. c See Figure 2 for a schematic neuroanatomical map showing the distribution of αS pathology.